UBI Publications by Field
Review publication of UBITh technology and products
- 1. Wang CY, Walfield AM. Site-specific peptide vaccines for immunotherapy and immunization against chronic diseases, and for veterinary applications. Vaccine 2005, 23:2049-2056.
UBITh® Aβ Immunotherapeutics (Alzheimer Disease)
- 1. Wang Y, Finstad CL, Walfield AM, Sia C, Sokoll KK, Chang TY, Fang XD, Hung CH, Birgit H-P and Windisch M. Site-specific UBITh® amyloid-vaccine for immunotherapy of Alzheimer's disease. Vaccine 2007, 25:3041-3052
Severe Acute Respiratory Syndrome (SARS)
- 1. Hseuh PR, Kao CL, Lee CN, Chen LK, Ho MS, Sia C, Fang XD, Lynn S, et al. Highly Specific SARS Antibody Test for Serosurveillance. Emerg. Infect. Diseases 2004, 10:1558-1562
Allergy, Including Vaccine
- 1. Wang CY, Walfield AM, Fang X, Hammerberg B, Ye J, Li ML, Shen F, Shen M, Alexander V, MacGlashan DW. Synthetic IgE peptide vaccine for immunotherapy of allergy. Vaccine 2003, 21: 1580-1590.
Foot-and-Mouth Disease Virus (FMDV)
- 1. Wang CY, Chang TY, Walfield AM, Ye J, Shen M, Chen SP, Li MC, Lin YL, Jong MH, Yang PC, Chyr N, Kramer E, Brown F. Effective synthetic peptide vaccine for foot-and-mouth disease in swine. Vaccine 2002, 20:2603-2610.
2. Wang CY, Chang TY, Walfield AM, Ye J, Shen M, Zhang ML, Lubroth J, Chen SP, Li MC, Lin YL, Jong MH, Yang PC, Chyr N, Kramer E, Brown F. Synthetic peptide-based vaccine and diagnostic system for effective control of FMD. Biologicals 2001, 29:221-228.
3. Shen F, Chen PD, Walfield AM, Ye J, House J, Brown F, Wang CY. Differentiation of convalescent animals from those vaccinated against foot-and-mouth disease by a peptide ELISA. Vaccine 1999, 17:3039-3049.
- 1. Finstad CL, Wang CY, Kowalski J, Zhang M, Li ML, Li XM, Xia WG, Bosland MC, Murthy KK, Walfield AM, Koff WC, Zamb T. Synthetic luteinizing hormone releasing hormone (LHRH) vaccine for effective androgen deprivation and its application to prostate cancer immunotherapy. Vaccine 2004; 22: 1300-1313.
2. Ladd A, Walfield AM, Tsong, YY, Thau R. Active immunization alone or combined with LHRH-analogue treatment impedes growth of androgen-dependent prostatic carcinoma. Am J Reprod Immunol 1995; 34:200-206.
3. Ladd A, Tsong YY, Walfield AM, Thau R. Development of an antifertility vaccine for pets based on active immunization against luteinizing hormone-releasing hormone. Biol Repro, 1994; 51:1076-1083.
4. Ladd, A. Progress in the development of anti-LHRH vaccine. Am J Repro Immunol 1993; 29:189-194.
UBITh and Combinatorial Immunogens
- 1. Kuebler PJ, Nixon DF. Cytotoxic T cell induction with ratchet peptide libraries. Vaccine 1996; 14:1664-1670.
HIV Vaccine and Treatment
- 1. Geetha P. Bansal. A summary of the workshop on passive immunization using monoclonal antibodies for HIV/AIDS, held at the National Institute of Allergy and Infectious Diseases, Bethesda, 10 March 2006. Biologicals 2007, 35:367-371.
2. Wang, C.Y. et al. Synthetic AIDS vaccine by targeting HIV receptor. Vaccine 2002, 21:89-97.
3. Wang CY, Sawyer LSW, Murthy KK, Fang XD, Walfield AM, et al. Postexposure immunoprophylaxis of primary isolates by an antibody to HIV receptor complex. Proc. Natl. Acad. Sci. USA 1999; 96:10367-10372.
4. Wang CY, Looney DJ, Li ML, Walfield AM, Ye J, Hosein B, Tam JP & Wong-Staal F. Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen. Science 1991; 254: 285-288.
5. Koff WC. The next steps towards a global AIDS vaccine. Science 1994: 266:1335-1337.
6. Zhang AQ, Geisler SC, Smith AD, Resnick DA, Li ML, Wang CY, et al. A disulfide-bound HIV-1 V3 loop sequence on the surface of human rhinovirus 14 induces neutralizing responses against HIV-1. Biol Chem 1999; 380:365-374.
7. Li D, Forrest BD, Li Z, Xue P, Hanson CV, Duan S, Cheng H, Li M, Wang CY, et al. International clinical trials of HIV vaccines: II. phase I trial of an HIV-1 synthetic peptide vaccine evaluating an accelerated immunization schedule in Yunnan, China. Asian Pac J Allergy Immunol 1997; 15:105-113.
8. Singh M, McGee JP, Li XM, Koff W, Zamb T, Wang CY, et al. Biodegradable microparticles with an entrapped branched octameric peptide as a controlled-release HIV-1 vaccine. J Pharmaceut Sci 1997; 66:1229-1233.
9. Tsuji T, Hamajima K, Fukushima J, Xin KQ, Koff WC, et al. Enhancement of cell-mediated immunity against HIV-1 induced by coinnoculation of plasmid-encoded HIV-1 antigen with plasmid expressing IL-12. J Immunol 1997; 158:4008-4013.
10. Okuda K, Xin KO, Tsuji T, Bukawa H, Tanaka S, Koff WC, et al. DNA vaccination followed by macromolecular- multicomponent peptide vaccination against HIV-1 induces antigen-specific immunity. Vaccine 1997; 15:1049-1056.
11. Phanuphak P, Teeratakulpixarn S, Sarangbin S, Nookhai S, Ubolyam S, Sirivichayakul S, Leesavan A, Forrest BD, Hanson CV, Li ML, Wang CY, et al. International clinical trials of HIV vaccines: I. Phase I trial of an HIV-1 synthetic peptide vaccine in Bangkok, Thailand. Asian Pac J Allerg Immunol 1997; 15:41-48.
12. Gorse GJ, Keefer MC, Belshe RB, Matthews TJ, Forrest BD, et al. A dose-ranging study of a prototype synthetic HIV-1 MN V3 branched peptide vaccine. J Infect Dis 1996; 173:330-339.
13. Koff WC, Schultz AM. Progress and challenges toward an AIDS vaccine: Brother, can you spare a paradigm. J Clin Immunol 1996; 16:127-133.
14. Richardson JJ, McGee JP, Gumear D, Potts B, et al. Controlled release antigen delivery systems for mucosal immunization with a HIV-1 peptide in small animal models. Proceed Intern Symp Control Rel Bioact Mater 1994; 21.
15. Walfield AM, Li ML, Looney DJ, Hosein B, Wong-Staal F & Wang CY. High-titer neutralization of multiple HIV-1 isolates by radially branched immunogens. In: Koff WC et al. eds. AIDS Research Reviews Vol. 3. New York: Marcel Dekker, Inc. 1993; 345-360.
16. Looney DJ, Li M, Walfield A, Hosein B, Badel P, Wang CY & Wong-Staal F. Type-specific and cross-reactive neutralizing antisera against HIV elicited by V3-peptide heptalysine octomers. AIDS Res Hum Retroviruses 1992; 8:1381.
17. Walfield AM, Li ML, Ye J, Hosein B, Fang XD, Wang CY, Looney DJ & Wong-Staal F. Induction of high-titer persistent neutralizing antibodies by HIV-1 V3 octa-branched peptides. Vaccines 92: Modern Approaches to New Vaccines Including Prevention of AIDS, Chanock RM et al (ed), Cold Spring Harbor Laboratory Press, 1992; 211-215.
HIV and HTLV Diagnostics
- 1. Wang JG, Steel S, Wisniewolski R & Wang CY. Detection of antibodies to HTLV-III using a synthetic peptide of 21 amino acid residues corresponding to a highly antigenic segment of gp41 envelope protein. Proc Natl Acad Sci USA 1986; 83: 6159-6163.
2. Khabbaz RF, Onorato IM, Cannon RO, Hartley TM, Hosein B, et al. Seroprevalence of HTLV-I and HTLV-II among intravenous drug users and persons in clinics for sexually transmitted diseases. N Eng J Med 1992; 326:375-380.
3. Wang CY. Synthetic-peptide-based immunodiagnosis of retrovirus infection: current status and future prospects. In “Synthetic Peptides in Biotechnology.”, Edited by A. Mizrahi, Adv. in Biotechnological Processes. 1988; 10: 131-148.
4. Gonzalez L, Boyle RW, Zhang M, Castillo J, Whittier S, Della-Latta P, Clarke LM, George JR, Fang XD, Wang JG, Hosein B, Wang CY. Synthetic-peptide-based enzyme-linked immunosorbent assay for screening human serum or plasma for antibodies to HIV-1 and 2. Clin Diag Lab Immunol 1997; 4:598-603.
5. Maytel J, Horowitz S, L ipper S, Poiesz B, Wang CY & Siegal FP. Progressive nemaline rod myopathy in a woman coinfected with HIV-1 and HTLV-2. Mt Sinai J Med 1993; 60:242.
6. Hosein B, Present W, Wang CY & Fang CT. Synthetic peptide-based EIAs to distinguish HTLV-I from HTLV-II infection. Transfusion 1990; 30S: 513.
7. Coulis PA, Wang JJG, Kang EP, Present W & Wang CY. Peptide-based immunodiagnosis of retrovirus infection. Am Clin Prod Rev. Nov. 1987.
- 1. Hosein B, Fang CT, Popvsky MA, Ye J, Zhang M & Wang CY. Improved serodiagnosis of hepatitis C virus infection with synthetic peptide antigen from capsid protein. Proc Natl Acad Sci USA. 1991; 88: 3647-3651.
2. Hosein B, Fang X & Wang CY. Anti-HCV, anti-GOR, and autoimmunity. Lancet 1992; 339: 871.
3. Prince AM, Brotman B, Inchauspe G, Pascual D, Nasoff M, Hosein B & Wang CY. Patterns and prevalence of hepatitis type C infection in post-transfusion non-A, non-B hepatitis. J Inf Dis 1993; 167: 1296-1301.
4. Quiroga JA, van Binsbergen J, Wang CY, Pardo M, Navas S, Trines C, Herrero M & Carreno V. Immunoglobulin M antibody to hepatitis C virus core antigen: Correlations with viral replication, histological activity, and liver disease outcome. Hepatol 1995; 22:1635-1640.
5. DeVault KR, Friedman LS, Westerberg S, Hosein B, et al. Hepatitis C in sickle cell anemia. J Clin Gastroenterol 1994; 18:206-209.
6. Silva AE, Hosein B, Boyle RW, Fang CT, Shindo M, et al. Diagnosis of chronic hepatitis C: comparison of immunoassays and the polymerase chain reaction. Am J Gastroenterol 1994; 89:493-496.
7. Sheu JC, Wang JT, Wang TH, Wang CY, et al.: Prevalence of hepatitis C viral infection in a community in Taiwan. Detection by synthetic peptide-based assay and polymerase chain reaction. J Hepatol 1993; 17: 192-198.
8. Wang JT, Wang TH, Sheu JC, Tsai SJ, Hsieh YS, Lin DT, Wang CY & Chen DS. Hepatitis C virus infection in volunteer blood donors in Taiwan. Evaluation by hepatitis C antibody assays and the polymerase chain reaction. Arch Pathol Lab Med 1993; 117:152-156.
9. Sheu JC, Huang GT, Shih LN, Lee WC, Chou HC, Wang JT, Lee PH, Lai MY, Wang CY, Yang PM, et al. Hepatitis C and B viruses in hepatitis B surface antigen-negative hepatocellular carcinoma. Gastroenterology 1992; 103:1322-1327.
10. Wang JT, Wang TH, Sheu JC, Lin JT, Wang CY & Chen DS. Posttransfusion hepatitis revisited by hepatitis C antibody assays and polymerase chain reaction. Gastroenterology 1992; 103: 609-616.
Vaccine Formulation and Controlled Release
- 1. Singh M, Li XM, Wang H, McGee JP, Zamb T, Koff W, Wang CY, and O’Hagan DT. Controlled release microparticles as a single dose diphtheria toxoid vaccine: immunogenicity in small animal models. Vaccine 1998; 16:346-352.
2. Singh M, Hioe C, Qiu H, Li XM, Wang CY, Koff W, Zamb T, and Nixon DF. CTL induction using synthetic peptides delivered in emulsions – critical role of the formulation procedure. Vaccine 1997; 15:1773-1778.
3. Singh M, Li XM, McGee JP, Zamb T, Koff W, Wang CY, and O’Hagan DT. Controlled release microparticles as a single dose hepatitis B vaccine: evaluation of immnogenicity in mice. Vaccine 1997; 15:475-481.
4. Singh M, Li XM, Wang H, McGee JP, Zamb T, Koff W, Wang CY, and O’Hagan DT. Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine. Infect Immun 1997; 65:1716-1721.
5. McGee JP, Singh M, Li XM, Qiu H, O’Hagan DT. The encapsulation of a model protein in poly (D,L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility. J Microencapsul 1997; 14:197-210.
6. Hioe CE, Qiu H, Chen PD, Bian Z, Li ML, Li J, Singh M, Kuebler P, McGee P, O’Hagan D, Zamb T, Koff W, Allsopp C, Wang CY, and Nixon DF. Comparison of adjuvant formulations for cytotoxic T cell induction using synthetic peptides. Vaccine 1996: 14:412-418.
7. Nixon DF, Hioe C, Chen PD, Bian Z, Kuebler P, Li ML, Qiu H, Li XM, Singh M, Richardson J, McGee P, Zamb T, Koff W, Wang CY & O’Hagan D. Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. Vaccine 1996; 14:1523-1530.
8. O'Hagan DT. Microparticles as oral vaccines. In Novel Delivery Systems for Oral Vaccines, O'Hagan ed., CRC Press, pp 175-205, 1994.
Monoclonal Antibody Technology and Engineering
- 1. Shimazaki C, Wisniewolski D, Scheinberg D, Atzpodien J, Strife A, Gulati S, Fried J, Wismienolski R, Wang CY & Clarkson B. Elimination of myeloma cells from bone marrow by using monoclonal antibodies and magnetic immunobeads. Blood 1988; 72: 1248.
2. Rinnooy-Kan EA, Wright SD, Welte K & Wang CY. Fc receptors on monocytes cause OKT-3 treated lymphocytes to internalize T3 and secrete IL-2. Cell Immunol 1986; 98: 181.
3. Fried J, Shimazaki C, Perez AC, Wisniewolski R & Wang CY. Application of flow cytometry to the analysis of multiple myeloma cells and their progenitors. Flow Cytometry Boca Roton, Fl. CRC. 1986.
4. Wang CY, Bushkin Y, Pica R, Lane CL, McGrath H & Posnett DN. Stimulation and expansion of a human T cell subpopulation by a monoclonal antibody to T cell receptor molecule. Hybridoma 1986; 5: 179.
5. Posnett DN, Folkl RJ & Wang CY. A hairy cell leukemia-associated antigen (HC2) has a distinct role in normal B cell differentiation. Leukemia 1987; 1: 3832.
6. Posnett D, Wang CY & Friedman SM. Inherited polymorphism of the human T cell antigen receptor detected by a monoclonal antibody. Proc Natl Acad Sci USA 1986; 83: 7888-7892.
7. Tse DB, Al-Haiden M, Pernis B, Cantor CR & Wang CY. Intracellular accumulation of T cell receptor complex molecules in a human T leukemia cell line. Science 1986; 234: 748.
8. Al-Katib A, Wang CY & Koziner B. Distribution of a new B cell associated surface antigen (BL7) detected by a monoclonal antibody in human leukemic disorders. Cancer Research 1985; 45: 3058.
9. Schwarting R, Stein H & Wang CY. Monoclonal antibodies S-HCL1 and S-HCL3 allow the diagnosis of hairy cell leukemia. Blood 1985; 65: 974.
10. Schwarting R, Welte K, Chiorazzi N, Ralph P, Lane CL, Long CW, & Wang CY. Biochemical characterization and purification of human B cell stimulatory factor (BSF). Eur J Immunol 1985; 15: 632.
- 1. Al-Katib A, Wang CY, McKenzie S, Clarkson BD & Koziner B. Phorbol ester-induced hairy cell features on chronic lymphocytic leukemia cells in vitro. Am J Hematology 1992; 40: 264.
2. Kao HT, Gregerson PK, Tang JC, Takahashi T, Wang CY & Silver J. Molecular analysis of HLA class genes in two DR6w-related haplotypes, DRw13 DQw1 and DRw14 DQw3. J Immunol 1989; 142: 1743.
3. Takahashi TC, Kao HT, Tang JC, Gregerson PK, Silver J & Wang C Y. Molecular diversity of HLA-DRw6 haplotypes. Immunobiology of HLA 1988; 2: 218.
4. Sung SSJ, Bjorndahl JM, Wang CY, Kao HT & Fu SM. Production of tumor necrosis factor/cachectin by human T cell lines and peripheral blood T lymphocytes stimulated by PMA and anti-CD3 antibody. J Exp Med 1988; 167: 937-953.
5. Sung SSJ, Jung LKL, Walters JA, Chen W, Wang CY & Fu SM. Production of tumor necrosis factor/cachetin by human B cell lines and tonsillar B cells. J Exp Med 1988; 168: 1539-1551.
6. Gottlieb AB, Lifshitz B, Fu SM, Staiano-Coico L, Wang CY & Carter DM. Expression of HLA-DR molecules by keratinocytes and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques. J Exp Med 1986; 164: 1013-1028.
7. Gregerson P, Shen M, Song Q, Wang CY, et al. Molecular diversity of HLA-DR4 haplotypes. Proc Natl Acad Sci USA 1986; 83: 2642-2646.
8. Buskin Y, Posnett DN, Pernis B & Wang CY. A new HLA-linked T cell membrane molecule, related to the beta chain of the clonotypic receptor, is associated with T3. J Exp Med 1986; 164: 458-473.
9. Bushkin Y, Chorney MJ, Diamante E, Lane CL, Fu SM & Wang CY. Biochemical characterization of a p43,12 complex: comparison to human and murine class I molecules. Mol Immunol 1985; 22: 695.
10. Knowles DM, Dodson L, Burke JS, Wang M, Bonetti F, Pelicci P, Flug F, Dalla-Favera R & Wang CY. SIg- ("Null-cell") non-Hodgkin's lymphomas: multiparametric determination of their B- or T-cell lineage. Am J Path 1985; 120: 356.
11. Flug F, Dodson L, Wang CY, Wolff JA, Rausen A, Guarini L, & Knowles DM. B lymphocyte associated differentiation antigen expression by "non-B, non-T" acute lymphoblastic leukemia. Leu Res 1985; 9: 1051.
12. Buskin Y, Kunkel HG, Pernis B & Wang CY. Evidence for a second receptor-like molecule in a human T cell leukemia. In: "Cell Biology of the Major Histocompatibility Complex." Edited by B. Pernis, and H.J. Vogel, New York, Academic Press. 1985; pp173-183.